Alembic Pharmaceuticals Limited share price
NSE: APLLTD · ISIN INE901L01018
Key numbers
- Market cap
- ₹ 16,978 Cr
- Current price
- ₹ 863.75
- 52-week high / low
- ₹ 998 / 636
- Stock P/E
- 24.5
- Book value
- ₹ 288.7
- Dividend yield
- 1.39%
- ROCE
- 11.6%
- ROE
- 12.4%
- Debt to equity
- 0.25
- Sales growth (3 yrs)
- 9.5%
- Profit growth (3 yrs)
- 25.4%
- 1-year return
- -6.1%
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,770 | 1,711 | 1,876 | 1,848 | 2,150 |
| Operating profit | 272 | 281 | 294 | 228 | 332 |
| Net profit | 157 | 154 | 133 | 203 | 173 |
| EPS (₹) | 7.98 | 7.85 | 6.76 | 10.31 | 8.80 |
Concall summary (2026-08-10)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- As a result, we believe the overall growth outlook for the company can improve from the low double-digit range that we had discussed earlier to closer to the mid-teen range for FY27.
- Listen, so I think when we give a guidance, we have to give a guidance that we are 100% can achieve.
Growth & demand
- During the quarter, consolidated revenue grew by 26% year- on-year supported by growth across all our major businesses.
- U.S. revenues grew 49% year-on-year, supported by volume growth, new launches, especially Bosutinib and improving utilization of our manufacturing assets.
Margins & costs
- Reported EBITDA grew at 21% year-on-year to INR348 crores with EBITDA margin at 16%.
- So we did about 16% margins in FY26, and we believe that the margins -- the underlying core margins will improve.
Capex & expansion
- We also continued investments in manufacturing capabilities, debottlenecking initiatives and capacity enhancement programs that will support future growth and improve operating leverage.
- So, depreciation is actually the intangible assets that we acquired because of -- driven by the US branded business expansion, the product acquisition that we did.
Balance sheet & cash
- Profit before tax grew at 17% year-on-year to INR223 crores, reflecting the strength of the underlying operating performance and better operating leverage across the business.
- So gross debt was about -- we are at around INR1,600 crores of gross debt and 2 things have happened.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.